Exploring Providers' Behaviors, Attitudes, and Preferences on the Treatment of Pulmonary Arterial Hypertension With Endothelin Receptor Antagonist (ERA) + Phosphodiesterase‐5 Inhibitors (PDE5i)

Documenti analoghi

• Qualitative Interviews of Physicians Managing Patients With Methamphetamine‐Associated Pulmonary Arterial Hypertension: Understanding the Unmet Medical Needs From a Provider Lens
  di: John F. Kingrey, et al.
  Pubblicazione: (2026)
• Prognosis and Treatment With Phosphodiesterase 5 Inhibitors in Combined Post‐ and Precapillary Pulmonary Hypertension: A Propensity Score‐Matched Analysis From the Hellenic Pulmonary Hypertension Registry
  di: Georgios E. Papadopoulos, et al.
  Pubblicazione: (2025)
• The Role of the Cellular Communication Network Protein Family in Pulmonary Arterial Hypertension
  di: Carly E. Byrd, et al.
  Pubblicazione: (2026)
• Prevalence and Economic Burden of Pulmonary Hypertension and Pulmonary Arterial Hypertension Among the Medicaid Population
  di: Marshaleen Henriques King, et al.
  Pubblicazione: (2025)
• Prognostic Role of Platelets in Pulmonary Arterial Hypertension
  di: Caio Julio Cesar dos Santos Fernandes, et al.
  Pubblicazione: (2025)